MedDay Secures €34 Million ($38.5M) New Funding

Biotin is an emerging therapy for the treatment of secondary progressive MS.
Post Reply
User avatar
ton
Family Member
Posts: 78
Joined: Thu May 27, 2010 2:00 pm

MedDay Secures €34 Million ($38.5M) New Funding

Post by ton »

Please visit this web:
http://www.medday-pharma.com/
User avatar
CureOrBust
Family Elder
Posts: 3374
Joined: Wed Jul 27, 2005 2:00 pm
Location: Sydney, Australia

Re: MedDay Secures €34 Million ($38.5M) New Funding

Post by CureOrBust »

A direct link: http://www.medday-pharma.com/news-and-e ... w-funding/
Friday, April 08, 2016
MedDay Secures €34 Million ($38.5M) New Funding
Edmond de Rothschild Investment Partners led the Series B financing alongside existing investors Sofinnova Partners and InnoBio. Large Venture also participated in the operation.

Funds will drive a confirmatory phase 3 study in US to treat progressive multiple sclerosis with MedDay’s wholly-owned lead candidate, MD1003
Does anyone know if the following statement only relates to people who were in the original studies? or is there a method to access the MD100 (as opposed to sourcing your own Biotin)?
The drug is already commercialized in some European countries under “named patient use”.
Post Reply

Return to “Biotin (Qizenday, Cerenday, MD1003)”